↓ Skip to main content

Clobazam monotherapy for partial-onset or generalized-onset seizures

Overview of attention for article published in Cochrane database of systematic reviews, October 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)

Mentioned by

twitter
2 tweeters
wikipedia
2 Wikipedia pages

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clobazam monotherapy for partial-onset or generalized-onset seizures
Published in
Cochrane database of systematic reviews, October 2014
DOI 10.1002/14651858.cd009258.pub2
Pubmed ID
Authors

Ravindra Arya, Vidhu Anand, Sushil K Garg, Benedict D Michael

Abstract

There is a need to expand monotherapy options available to a clinician for the treatment of new partial-onset or generalized-onset seizures. A Cochrane systematic review for clobazam monotherapy is expected to define its place in the treatment of new-onset or untreated seizures and highlight gaps in evidence.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 41 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 26%
Researcher 11 26%
Student > Master 4 10%
Student > Doctoral Student 4 10%
Student > Ph. D. Student 3 7%
Other 5 12%
Unknown 4 10%
Readers by discipline Count As %
Medicine and Dentistry 24 57%
Nursing and Health Professions 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Psychology 2 5%
Social Sciences 2 5%
Other 2 5%
Unknown 6 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2020.
All research outputs
#4,223,202
of 15,456,294 outputs
Outputs from Cochrane database of systematic reviews
#6,892
of 11,188 outputs
Outputs of similar age
#60,052
of 232,716 outputs
Outputs of similar age from Cochrane database of systematic reviews
#181
of 246 outputs
Altmetric has tracked 15,456,294 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 11,188 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,716 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 246 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.